GSK signs agreement to support pandemic preparedness in Europe
GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for the reservation of future production and supply of 85 million doses of its pandemic influenza vaccine Adjupanrix [pandemic influenza vaccine (split virion, inactivated, adjuvanted)].
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news
More News: Bird Flu | Bird Flu (H5N1 Avian Influenza) Vaccine | Contracts | Emergency Medicine | Flu Pandemic | Influenza | Influenza Vaccine | Pandemics | Pharmaceuticals | Vaccines